Friday, December 6, 2024

CATEGORY

Pharma

UK Diabetes Device Market Projects $2 Billion by 2032

Inferences:Government initiatives, particularly those supported by the NHS, are crucial in driving market growth. The aging population significantly contributes to the increasing demand...

NSW Government Allocates $10.7M to Enhance Drug and Alcohol Support in Far West

Key TakeawaysIncreased accessibility to specialized treatment services in rural areas. Focused support for Aboriginal communities through culturally appropriate programs. Enhanced collaboration between health...

WHO Endorses First Single-Dose Treatment for P. vivax Malaria

Key TakeawaysTafenoquine's approval accelerates malaria elimination efforts in multiple countries. The need for G6PD testing ensures safe administration, mitigating potential risks. Collaboration between...

Pacira Receives U.S. Patent to Protect EXPAREL Until 2044

Pacira BioSciences has bolstered its intellectual property portfolio by securing a new U.S. patent for its flagship pain therapy, EXPAREL. This latest achievement marks...

Inari Medical Secures Reimbursement for ClotTriever in Japan

Key TakeawaysThe creation of a new functional category by MHLW underscores the ClotTriever's distinct clinical benefits. The partnership with Medikit is pivotal for...

Sobi Highlights Robust Hematology Portfolio at ASH 2024

Sobi is set to present a comprehensive range of data and analyses at the 66th Annual Meeting of the American Society of Hematology (ASH)...

Vyepti Proves Effective in Reducing Severe Migraine Days, New Trial Shows

H. Lundbeck A/S announced promising results from the RESOLUTION Phase IV trial, demonstrating that Vyepti (eptinezumab) significantly reduces the frequency of migraine days in...

Gilead and Tubulis Form Exclusive Partnership to Develop ADC for Solid Tumors

Gilead Sciences, Inc. and Tubulis have forged a pivotal exclusive option and license agreement to spearhead the discovery and development of a cutting-edge antibody-drug...

FDA Accelerates Approval for Merck’s sac-TMT in Advanced Lung Cancer

Merck has secured the FDA’s Breakthrough Therapy designation for its investigational drug sacituzumab tirumotecan (sac-TMT). This approval targets patients battling advanced or metastatic nonsquamous...

Intra-Cellular Therapies Files FDA Supplemental Application for CAPLYTA in Depression Treatment

Intra-Cellular Therapies, a biopharmaceutical leader in central nervous system disorders, has taken a significant step by submitting a supplemental New Drug Application (sNDA) to...

Shionogi’s Cefiderocol Gains Australian Approval for Resistant Infections

Key TakeawaysCefiderocol’s approval in Australia broadens treatment options for resistant infections. Shionogi’s strategic partnerships enhance global accessibility to critical antibiotics. Clinical trial success...

KIMMTRAK Receives NHS Funding for Uveal Melanoma Treatment in England

A significant advancement in cancer treatment was marked today as Immunocore secured reimbursement approval from England's National Health Service (NHS) for KIMMTRAK, offering a...

China Approves PharmaMar’s Zepzelca for Aggressive Lung Cancer

PharmaMar Group has successfully expanded its global footprint as Luye Pharma Group Ltd. secures conditional approval from China's NMPA for Zepzelca (lurbinectedin). This milestone...

Novo Nordisk Reveals New Sickle Cell and Hemophilia Findings at ASH 2024

Novo Nordisk is set to showcase 13 new abstracts, including three oral presentations, at the 66th Annual Meeting and Exposition of the American Society...

ADD4KIDS Launches Final Webinar to Boost Pediatric Innovation in Europe

On December 16 at 11:00 AM, the ADD4KIDS project will host its third and final webinar, marking the culmination of efforts to accelerate pediatric...

Latest news